160 related articles for article (PubMed ID: 26313663)
21. Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma.
Hedner C; Borg D; Nodin B; Karnevi E; Jirström K; Eberhard J
PLoS One; 2016; 11(2):e0148101. PubMed ID: 26844548
[TBL] [Abstract][Full Text] [Related]
22. HER2 expression in oesophageal carcinoma and Barrett's oesophagus associated adenocarcinoma: An Australian study.
Nagaraja V; Shaw N; Morey AL; Cox MR; Eslick GD
Eur J Surg Oncol; 2016 Jan; 42(1):140-8. PubMed ID: 26422587
[TBL] [Abstract][Full Text] [Related]
23. HER2-low in gastro-oesophageal adenocarcinoma: a real-world pathological perspective.
Angerilli V; Parente P; Campora M; Ugolini C; Battista S; Cassoni P; Gambella A; Cavallin F; De Lisi G; Vanoli A; Grillo F; Mastracci L; Fassan M
J Clin Pathol; 2023 Dec; 76(12):815-821. PubMed ID: 37055161
[TBL] [Abstract][Full Text] [Related]
24. The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis.
Fassan M; Pizzi M; Realdon S; Balistreri M; Guzzardo V; Zagonel V; Castoro C; Mastracci L; Farinati F; Nitti D; Zaninotto G; Rugge M
Hum Pathol; 2013 Sep; 44(9):1804-10. PubMed ID: 23618359
[TBL] [Abstract][Full Text] [Related]
25. HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas.
Reis H; Herold T; Ting S; Worm K; Huber U; Christoph DC; Eberhardt WE; Kostbade K; Kasper S; Stamatis G; Welter S; Darwiche K; Karpf-Wissel R; Theegarten D; Schmid KW; Schuler M; Wiesweg M
Lung Cancer; 2015 Apr; 88(1):34-41. PubMed ID: 25708529
[TBL] [Abstract][Full Text] [Related]
26. Human epidermal growth factor receptor 2 overexpression and amplification in endoscopic biopsies and resection specimens in esophageal and junctional adenocarcinoma.
van Hagen P; Biermann K; Boers JE; Stoss O; Sleddens HF; van Lanschot JJ; Dinjens WN; Rueschoff J; Wijnhoven BP
Dis Esophagus; 2015; 28(4):380-5. PubMed ID: 24611982
[TBL] [Abstract][Full Text] [Related]
27. HER2 testing in gastric and gastroesophageal adenocarcinomas.
Vakiani E
Adv Anat Pathol; 2015 May; 22(3):194-201. PubMed ID: 25844677
[TBL] [Abstract][Full Text] [Related]
28. Concordance of HER2 expression in paired primary and metastatic sites of gastric and gastro-oesophageal junction cancers.
Wong DD; Kumarasinghe MP; Platten MA; de Boer WB
Pathology; 2015 Dec; 47(7):641-6. PubMed ID: 26517644
[TBL] [Abstract][Full Text] [Related]
29. FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation.
Betts G; Valentine H; Pritchard S; Swindell R; Williams V; Morgan S; Griffiths EA; Welch I; West C; Womack C
Virchows Arch; 2014 Feb; 464(2):145-56. PubMed ID: 24306956
[TBL] [Abstract][Full Text] [Related]
30. [Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma].
Zhang X; Wu Y; Gong J; Lu Z; Zhou J; Wang X; Lu M; Li J; Cao Y; Li Y; Li J; Shen L
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):223-7. PubMed ID: 24785285
[TBL] [Abstract][Full Text] [Related]
31. Biochemical analysis and subcellular distribution of E-cadherin-catenin in adenocarcinomas of the gastro-oesophageal junction.
Wijnhoven BP; Tucker ET; Dinjens WN; Tilanus HW; Pignatelli M
Anticancer Res; 2004; 24(3a):1369-75. PubMed ID: 15274297
[TBL] [Abstract][Full Text] [Related]
32. Clinical features and course of brain metastases in triple-negative breast cancer: comparison with human epidermal growth factor receptor 2-positive and other type at single institution in Korea.
Jang G; Lee SS; Ahn JH; Jung KH; Lee H; Gong G; Kim HH; Ahn SD; Son BH; Ahn SH; Kim SB
Breast Cancer Res Treat; 2011 Jul; 128(1):171-7. PubMed ID: 21519835
[TBL] [Abstract][Full Text] [Related]
33. Discordance in HER2 status between primary gastric adenocarcinoma tumors and cells from the corresponding malignant effusions.
Kim H; Son SM; Woo CG; Lee OJ; Kim DH; Yun HY; Yun J; Kim HK; Yang Y; Han HS
BMC Cancer; 2019 Sep; 19(1):834. PubMed ID: 31477048
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study.
Langer R; Von Rahden BH; Nahrig J; Von Weyhern C; Reiter R; Feith M; Stein HJ; Siewert JR; Höfler H; Sarbia M
J Clin Pathol; 2006 Jun; 59(6):631-4. PubMed ID: 16731604
[TBL] [Abstract][Full Text] [Related]
35. Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma.
Safran H; Dipetrillo T; Akerman P; Ng T; Evans D; Steinhoff M; Benton D; Purviance J; Goldstein L; Tantravahi U; Kennedy T
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):405-9. PubMed ID: 17097832
[TBL] [Abstract][Full Text] [Related]
36. Human epidermal growth-factor receptor 2 overexpression in gastric carcinoma in Thai patients.
Sornmayura P; Rerkamnuaychoke B; Jinawath A; Euanorasetr C
J Med Assoc Thai; 2012 Jan; 95(1):88-95. PubMed ID: 22379747
[TBL] [Abstract][Full Text] [Related]
37. Central nervous system relapse in patients with untreated HER2-positive esophageal or gastroesophageal junction adenocarcinoma.
Yoon HH; Lewis MA; Foster NR; Sukov WR; Khan M; Sattler CA; Wiktor AE; Wu TT; Jenkins RB; Sinicrope FA
Int J Cancer; 2016 Oct; 139(7):1626-31. PubMed ID: 27198655
[TBL] [Abstract][Full Text] [Related]
38. Discordance in HER2 Status in Gastro-esophageal Adenocarcinomas: A Systematic Review and Meta-analysis.
Creemers A; Ter Veer E; de Waal L; Lodder P; Hooijer GKJ; van Grieken NCT; Bijlsma MF; Meijer SL; van Oijen MGH; van Laarhoven HWM
Sci Rep; 2017 Jun; 7(1):3135. PubMed ID: 28600510
[TBL] [Abstract][Full Text] [Related]
39. Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status.
Wang T; Hsieh ET; Henry P; Hanna W; Streutker CJ; Grin A
Hum Pathol; 2014 May; 45(5):970-5. PubMed ID: 24656529
[TBL] [Abstract][Full Text] [Related]
40. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]